NCCN Tumor Boards: Managing Unique Toxicities and Immune-Related Adverse Effects of Treatment for Hodgkin Lymphoma
Course Provider
Certifications
Learning Objectives
Participants will discuss key results of the SWOG S1826, ECHELON-1, and GHSG HD21 studies.
Participants will describe how the treatment paradigm for advanced stage classic Hodgkin lymphoma has shifted in recent years.
Participants will identify unique toxicities of brentuximab vedotin and nivolumab.
Course Offering: Meeting, Seminar, Workshop, or Webinar - Live (delivered in real time)
Domain Focus: Psychosocial Concepts and Support Systems